MyCartis acquires ANTELOPE Dx platform technology

(13-12-2018) The biotech company MyCartis has announced the addition of a point-of-need testing technology, ANTELOPE Dx (developed at Ghent University), to complement its immuno-assay technology offering.

ANTELOPE Dx is an immuno-diagnostic platform in development, that aims to offer clinical lab performance with the ease-of-use of a pregnancy test at a consumer price tag. The technology originated from UGent, Belgium, under supervision of Professor Peter Bienstman, in the Photonics Research Group of Professor Roel Baets, with Jan-Willem Hoste as lead investigator. Jan-Willem Hoste will play a crucial role in the further development of the technology, the platform and the test menu.
The platform consists of a disposable cartridge and a very small reader module. The heart of the technology is a silicon photonic chip inside the cartridge. This single use test can measure different parameters simultaneously targeting the quality of the large clinical analyzers. ANTELOPE Dx will make it possible to get clinical grade diagnostics at home or at the doctor’s office within minutes.

Peter Bienstman, professor at Ghent University, comments “This technology has been in development for more than ten years, and we’re excited and proud that ANTELOPE Dx and MyCartis will partner up to bring this point-of-need testing to the patient.”

Jan-Willem Hoste, ANTELOPE Dx lead in MyCartis, adds: “Both digital health solutions and point-of-care diagnostics are evolving rapidly and offer solutions for decentralized healthcare, each in their own way. We believe the Antelope technology will connect the dots: affordable and easy to use, yet without compromising on quality.” “We are very excited that we can contribute to bringing actionable clinical diagnostic guidance closer to the patient”, says Hilde Windels, CEO of MyCartis “We will work hard with a very dedicated, experienced team to provide a solution which is affordable, fast and reliable, three necessary ingredients to be at the forefront of next generation point-of-need testing.”